Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Medtronic plc. A complete text table follows the diagram.
Four medical-technology platforms balance implantable devices, surgical systems and recurring therapy demand across an almost even U.S.-international sales split
Swipe to explore
Other and reconciliation combines $32M directly reported other-segment sales with a $1M displayed-line rounding bridge. A separate $1M statement-rounding source reconciles operating expense lines to reported operating profit.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cardiovascular | 1 | $3.5B | 38.3% of sales · +14% |
| Neuroscience | 1 | $2.6B | Spine, therapies and neuromodulation |
| Medical Surgical | 1 | $2.2B | Surgery, endoscopy and monitoring |
| Diabetes | 1 | $796M | Fastest-growing segment · +15% |
| Other & reconciliation | 1 | $33M | Other segment plus rounding |
| Net sales | 2 | $9.0B | 8.7% year-over-year growth |
| Statement rounding | 2 | $1M | Displayed-line reconciliation |
| Operating profit | 3 | $1.5B | 16.2% operating margin |
| Cost of products sold | 3 | $3.3B | Manufacturing and supply chain |
| Research & development | 3 | $722M | 8.0% of sales |
| Selling, general & administrative | 3 | $3.0B | Global commercial and service network |
| Intangible amortization | 3 | $441M | Acquired technologies |
| Restructuring, litigation & other | 3 | $174M | Restructuring and special operating items |
| Non-operating income | 3 | $121M | Other income, net |
| Income before tax | 4 | $1.4B | 15.6% of sales |
| Interest expense | 4 | $181M | Debt financing |
| Net income | 5 | $1.1B | Reported bottom line |
| Income tax | 5 | $254M | 18.1% effective rate |
| From | To | Value |
|---|---|---|
| Cardiovascular | Net sales | $3.5B |
| Neuroscience | Net sales | $2.6B |
| Medical Surgical | Net sales | $2.2B |
| Diabetes | Net sales | $796M |
| Other & reconciliation | Net sales | $33M |
| Net sales | Operating profit | $1.5B |
| Statement rounding | Operating profit | $1M |
| Net sales | Cost of products sold | $3.3B |
| Net sales | Research & development | $722M |
| Net sales | Selling, general & administrative | $3.0B |
| Net sales | Intangible amortization | $441M |
| Net sales | Restructuring, litigation & other | $174M |
| Operating profit | Income before tax | $1.3B |
| Non-operating income | Income before tax | $121M |
| Operating profit | Interest expense | $181M |
| Income before tax | Net income | $1.1B |
| Income before tax | Income tax | $254M |